Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

• Published in: Blood Vol. 138; no. Supplement 1; p. 3603
• Main Authors: Breccia, Massimo, Luciano, Luigia, Annunziata, Mario, Attolico, Imma, Malato, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Scortechini, Anna Rita, Cascavilla, Nicola, Di Renzo, Nicola, Impera, Stefana, Lunghi, Monia, Santoro, Marco, Castagnetti, Fausto, Maggi, Alessandro, Sargentini, Valeria, Piciocchi, Alfonso, Galimberti, Claudia, Iurlo, Alessandra
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 23.11.2021

Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying...